Diabetes

Molecular therapy for Metabolic diseases: Rolipram, a phosphodiesterase-4 inhibitor and an investigational drug for depression, autoimmune diseases, Alzheimer’s disease,cognitive enhancement,spinal cord injury, asthma and COPD, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, increases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 10/February/2018, 6.55 am
Molecular therapy for Metabolic diseases: Rolipram, a phosphodiesterase-4 inhibitor and an investigational drug for depression, autoimmune diseases, Alzheimer’s disease,cognitive enhancement,spinal cord injury, asthma and COPD, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, increases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene.., 10/February/2018, 6.55 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published, in the June 8, 2011 Nature [One of…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing 17α-Estradiol and Aspirin  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/February/2018, 11.03 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing 17α-Estradiol and Aspirin  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 8/February/2018, 11.03 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Nordihydroguaiaretic acid and Aspirin  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 7/February/2018, 10.32 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Nordihydroguaiaretic acid and Aspirin  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 7/February/2018, 10.32 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: D-β-Hydroxybutyrate (D-βHB) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 6/February/2018, 6.58 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: D-β-Hydroxybutyrate (D-βHB) increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 6/February/2018, 6.58 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Molecular therapy for TIIDM and obesity-associated metabolic deficits: D-3-hydroxybutyrate (D3HB)  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 6/February/2018, 6.45 am
Molecular therapy for TIIDM and obesity-associated metabolic deficits: D-3-hydroxybutyrate (D3HB)  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 6/February/2018, 6.45 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more

Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: D-3-Hydroxybutyrate (3DHB) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 5/February/2018, 11.06 pm
Natural product-based therapy for TIIDM and obesity-associated metabolic deficits: D-3-Hydroxybutyrate (3DHB) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 5/February/2018, 11.06 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more
Start Typing